Global Cannabis Applications Corp (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative smartphone applications for the cannabis industry, announces it has entered into discussions with respect to medical cannabis technology applications including Artificial Intelligence (“AI”), data scraping and Blockchain delivery with a leading Australian technology accelerator and aggregator, Fintechgration.
In September 2017, GCAC intends to commence trials on a proprietary AI regulatory monitoring platform to manage international ISO standards for medical cannabis.  The data collected from this technology is anticipated to augment the existing data pool used within GCAC’s Citizen Green App suite and proprietary ‘Pain to Strain’ database.
AI compliance technology proposes to help deliver a near bullet proof auditing system for regulatory compliance across global jurisdictions, and may have immediate application to ‘Schedule 8’ medical cannabis regulation in countries such as Australia.
Blockchain is a disruptive, secure, digital “distributed ledger” that is being heralded as a significant innovation that could have far reaching implications in health and financial industries.  The technology may be used to collect data from and improve medical cannabis supply chains.
These cutting-edge technologies coupled with Citizens Green’s “Pain to Strain’ database (built from over 10 years of field research tracking medicinal cannabis users seeking therapeutic remedies for multiple conditions including cancer and epilepsy), have the potential to generate significant improvements on data insights for ongoing clinical trials in the medical cannabis arena.
“This is an exciting new frontier.  GCAC eagerly anticipates exploring AI along with the application of Blockchain technology fed by dynamic social media to provide the basis for curating authoritative data for medical practitioners, researchers, providers and growers,” says Jason Webb, Managing Director of GCAC, Australia.
GCAC’s business is focused on ‘big data’, which will be aggregated through various technologies enabling users, patients, doctors, pharmacists, providers and practitioners to more easily identify key strains of cannabis that have the greatest benefit to targeted ailments for personal well being.  
States GCAC CEO, Brad Moore, “Our innovative approach to technology in the medical cannabis space alongside the rich data experience derived from our Citizen Green Apps will build the foundational blocks for understanding and participating in the growing world of medical cannabis.”
About Global Cannabis Applications Corp.
Global Cannabis is a global leader in designing, developing, marketing, and acquiring innovative mobile applications.  Used in over 25 countries, GCAC’s apps facilitate the proliferation of digital conversations by like-minded people.  Managed by digital industry experts, GCAC is focused on viral global expansion by providing the best user experience in each target market.  Its leading mobile platforms are Citizen Green, a family of apps dedicated to the digital world of all things cannabis; Foro, a peer-to-peer mobile ecommerce student marketplace; Opinit, an app that enables users to socially share their favourite online sentiment-driven content; and Truth, a one-to-one anonymous messaging app.
For more information about the Company, please visit online at www.cannappscorp.com, or review its profiles on the SEDAR website (www.sedar.com) and on the Canadian Securities Exchange’s website (www.thecse.com)
 
To schedule an interview, please contact:
Bradley Moore
Chief Executive Officer
Telephone:  514-561-9091
Email: bmoore@cannappscorp.com
For more information, please contact:
Corporate Communications
Telephone: 1.855.269.9554
Email: info@cannappscorp.com
www.cannappscorp.com
 
Forward-Looking Information
This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC.  Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC.  Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct.  Forward-looking statements contained in this news release are made as of the date of this news release.  GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. 
Click here to connect with Global Cannabis Applications Corp (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF)) to receive an Investor Kit.

Source: www.benzinga.com


Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less